|
DE3613736A1
(de)
*
|
1985-04-26 |
1986-10-30 |
Adalbert 8261 Reischach Hayduk |
Vorrichtung zur hautvertraeglichen befestigung von behandlungselementen der akupunktur-therapie am ohr von patienten
|
|
USRE35511E
(en)
*
|
1990-12-18 |
1997-05-20 |
Nakamura; Azuko |
Accessory for earring
|
|
US5097682A
(en)
*
|
1990-12-18 |
1992-03-24 |
Azuko Nakamura |
Accessory for earring
|
|
WO1993008712A1
(en)
*
|
1991-11-08 |
1993-05-13 |
Leona Gray Loureiro |
Jewelry and apparel fixation
|
|
FR2703568A1
(fr)
*
|
1993-04-09 |
1994-10-14 |
Muller Dominique |
Système de fixation de boucles d'oreilles.
|
|
US7060808B1
(en)
*
|
1995-06-07 |
2006-06-13 |
Imclone Systems Incorporated |
Humanized anti-EGF receptor monoclonal antibody
|
|
GB2304533A
(en)
*
|
1995-08-24 |
1997-03-26 |
Bun Wong |
Personal decoration composed of precious stone with magnet insert.
|
|
US5989178A
(en)
*
|
1997-04-02 |
1999-11-23 |
Chiu; Alexander Y. C. |
Magnetic ring
|
|
US20030224001A1
(en)
*
|
1998-03-19 |
2003-12-04 |
Goldstein Neil I. |
Antibody and antibody fragments for inhibiting the growth of tumors
|
|
FR2777364B1
(fr)
*
|
1998-04-08 |
2000-06-16 |
Andre Jevanoff |
Montre presentant un bloc-montre pourvu d'au moins une parure interchangeable formant bijou
|
|
ZA200007412B
(en)
*
|
1998-05-15 |
2002-03-12 |
Imclone Systems Inc |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
|
|
EP2042194A3
(en)
*
|
1999-05-14 |
2009-04-22 |
Imclone Systems, Inc. |
Treatment of refractory human tumors with epidermal growth factor receptor antagonists
|
|
GB2356291B
(en)
|
1999-11-13 |
2003-10-22 |
Rolls Royce Plc |
A workpiece clamping system
|
|
AU9500201A
(en)
*
|
2000-08-09 |
2002-02-18 |
Imclone Systems Inc |
Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
|
|
US6305192B1
(en)
|
2000-09-11 |
2001-10-23 |
Inverness Corporation |
Apparatus for increasing piercing safety
|
|
US20080008704A1
(en)
*
|
2001-03-16 |
2008-01-10 |
Mark Rubin |
Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
|
|
US6715315B1
(en)
|
2002-09-23 |
2004-04-06 |
Heart & Company |
Jewelry articles having magnetic elements and interchangeable settings
|
|
DE10320863B3
(de)
*
|
2003-05-09 |
2004-11-11 |
Siemens Audiologische Technik Gmbh |
Befestigung eines Hörhilfegerätes oder einer Otoplastik im Ohr
|
|
US7143607B2
(en)
*
|
2003-08-27 |
2006-12-05 |
Heart & Company |
Jewelry article having interchangeable setting and capture module
|
|
AU2004280064A1
(en)
*
|
2003-10-09 |
2005-04-21 |
Kyowa Hakko Kirin Co., Ltd. |
Genomically modified cell neutralized to serum-free system
|
|
WO2005090407A1
(en)
*
|
2004-03-19 |
2005-09-29 |
Imclone Systems Incorporated |
Human anti-epidermal growth factor receptor antibody
|
|
EP1700533A1
(fr)
*
|
2005-03-11 |
2006-09-13 |
Bruno Fillacier |
Dispositif pour maintenir un objet d'orfèvrerie aux lobes des oreilles
|
|
EP1754991A1
(en)
*
|
2005-08-18 |
2007-02-21 |
Yu-Teng Hsiao |
Movable magnetic coupling system for securing a one-piece lens to a cap visor
|
|
US20070083237A1
(en)
*
|
2005-10-12 |
2007-04-12 |
Teruel Elberto B |
Magnetic therapeutic device and method of using the same
|
|
HUE029139T2
(hu)
|
2011-02-10 |
2017-02-28 |
Roche Glycart Ag |
Mutáns interleukin-2 polipeptidek
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
US8991210B1
(en)
|
2011-08-19 |
2015-03-31 |
Cary Stewart, Jr. |
Revolving jewelry system
|
|
MY171038A
(en)
|
2011-08-23 |
2019-09-23 |
Roche Glycart Ag |
Bispecific antigen binding molecules
|
|
US20130078250A1
(en)
|
2011-08-23 |
2013-03-28 |
Oliver Ast |
Bispecific t cell activating antigen binding molecules
|
|
WO2013026835A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Fc-free antibodies comprising two fab fragments and methods of use
|
|
EP2747781B1
(en)
|
2011-08-23 |
2017-11-15 |
Roche Glycart AG |
Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
|
|
EP3321286B1
(en)
|
2011-08-23 |
2021-01-06 |
Roche Glycart AG |
Bispecific t cell activating antigen binding molecules
|
|
BR112015002085A2
(pt)
|
2012-08-08 |
2017-12-19 |
Roche Glycart Ag |
proteína, polinucleotídeo, vetor, célula hospedeira, método para produzir a proteína, composição farmacêutica, uso da proteína, método de tratamento e invenção
|
|
US9771427B2
(en)
|
2012-08-09 |
2017-09-26 |
Roche Glycart Ag |
ASGPR antibodies and uses thereof
|
|
US20140044675A1
(en)
|
2012-08-10 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-2 fusion proteins and uses thereof
|
|
WO2014056783A1
(en)
|
2012-10-08 |
2014-04-17 |
Roche Glycart Ag |
Fc-free antibodies comprising two fab-fragments and methods of use
|
|
WO2014131711A1
(en)
|
2013-02-26 |
2014-09-04 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
JP6499087B2
(ja)
|
2013-02-26 |
2019-04-10 |
ロシュ グリクアート アーゲー |
二重特異性ｔ細胞活性化抗原結合分子
|
|
WO2014131712A1
(en)
|
2013-02-26 |
2014-09-04 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
UA118028C2
(uk)
|
2013-04-03 |
2018-11-12 |
Рош Глікарт Аг |
Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
|
|
RS58149B1
(sr)
|
2014-02-06 |
2019-02-28 |
Hoffmann La Roche |
Fuzioni proteini interleukina-2 i njihova upotreba
|
|
US20150325352A1
(en)
*
|
2014-05-07 |
2015-11-12 |
Anker Technology Co., Limited |
Magnet fixed device and an electronic device having the same or an accessory having the same
|
|
RS65573B1
(sr)
|
2014-08-04 |
2024-06-28 |
Hoffmann La Roche |
Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije
|
|
MX391388B
(es)
|
2014-11-14 |
2025-03-21 |
Hoffmann La Roche |
Moléculas de unión a antígeno que comprenden un trímero de ligando de la familia de tnf.
|
|
BR112017010513A2
(pt)
|
2014-11-20 |
2018-04-03 |
F. Hoffmann-La Roche Ag |
?cadeias leves comuns e métodos de uso?
|
|
WO2016146833A1
(en)
|
2015-03-19 |
2016-09-22 |
F. Hoffmann-La Roche Ag |
Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
HK1254967A1
(zh)
|
2015-10-02 |
2019-08-02 |
豪夫迈‧罗氏有限公司 |
结合间皮素和cd3的双特异性t细胞活化性抗原结合分子
|
|
CN108026177B
(zh)
|
2015-10-02 |
2021-11-26 |
豪夫迈·罗氏有限公司 |
双特异性抗cd19xcd3 t细胞活化性抗原结合分子
|
|
WO2017055385A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
|
|
US20180282410A1
(en)
|
2015-10-02 |
2018-10-04 |
Hoffmann-La Roche Inc. |
Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
|
|
KR20180073561A
(ko)
|
2015-10-02 |
2018-07-02 |
에프. 호프만-라 로슈 아게 |
이중특이적 항-ceaxcd3 t 세포 활성화 항원 결합 분자
|
|
WO2017055393A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
|
|
JP2018533930A
(ja)
|
2015-10-02 |
2018-11-22 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性ｔ細胞活性化抗原結合分子
|
|
WO2017055392A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
|
|
MA43724B1
(fr)
|
2016-03-22 |
2023-06-28 |
Hoffmann La Roche |
Molécules bispécifiques de cellules t activées par une protéase
|
|
EP3231813A1
(en)
|
2016-03-29 |
2017-10-18 |
F. Hoffmann-La Roche AG |
Trimeric costimulatory tnf family ligand-containing antigen binding molecules
|
|
WO2017194442A1
(en)
|
2016-05-11 |
2017-11-16 |
F. Hoffmann-La Roche Ag |
Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety
|
|
EP3243836A1
(en)
|
2016-05-11 |
2017-11-15 |
F. Hoffmann-La Roche AG |
C-terminally fused tnf family ligand trimer-containing antigen binding molecules
|
|
EP3243832A1
(en)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
|
|
US10882918B2
(en)
|
2016-09-30 |
2021-01-05 |
Hoffmann-La Roche Inc. |
Bispecific T cell activating antigen binding molecules
|
|
CN117752798A
(zh)
|
2016-12-19 |
2024-03-26 |
豪夫迈·罗氏有限公司 |
用靶向性4-1bb(cd137)激动剂的组合疗法
|
|
MX2019006954A
(es)
|
2016-12-20 |
2019-08-01 |
Hoffmann La Roche |
Terapia de combinacion de anticuerpos biespecificos anti-cd20/anti-cd3 y agonistas de 4-1bb (cd137).
|
|
WO2018178074A1
(en)
|
2017-03-29 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Trimeric antigen binding molecules specific for a costimulatory tnf receptor
|
|
JP7196094B2
(ja)
|
2017-03-29 |
2022-12-26 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
共刺激ｔｎｆ受容体のための二重特異性抗原結合分子
|
|
EP3601346A1
(en)
|
2017-03-29 |
2020-02-05 |
H. Hoffnabb-La Roche Ag |
Bispecific antigen binding molecule for a costimulatory tnf receptor
|
|
EP4201953A1
(en)
|
2017-04-03 |
2023-06-28 |
F. Hoffmann-La Roche AG |
Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
|
|
SG11201909218RA
(en)
|
2017-04-03 |
2019-11-28 |
Hoffmann La Roche |
Antibodies binding to steap-1
|
|
JP7148539B2
(ja)
|
2017-04-03 |
2022-10-05 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
免疫抱合体
|
|
CA3079036A1
(en)
|
2017-11-01 |
2019-05-09 |
F. Hoffmann-La Roche Ag |
Combination therapy with targeted ox40 agonists
|
|
IL272747B2
(en)
|
2017-11-01 |
2025-04-01 |
Hoffmann La Roche |
Bispecific antibodies 1 + 2
|
|
EP3502140A1
(en)
|
2017-12-21 |
2019-06-26 |
F. Hoffmann-La Roche AG |
Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
|
|
BR112020011469A2
(pt)
|
2017-12-21 |
2020-11-24 |
F. Hoffmann-La Roche Ag |
anticorpos, molécula de ligação ao antígeno biespecífica, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método para produzir um anticorpo, composição farmacêutica, uso do anticorpo, método de tratamento de uma doença e invenção
|
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
|
CA3092002A1
(en)
|
2018-03-13 |
2019-09-19 |
F. Hoffmann-La Roche Ag |
Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies
|
|
TWI841551B
(zh)
|
2018-03-13 |
2024-05-11 |
瑞士商赫孚孟拉羅股份公司 |
使用靶向4-1bb (cd137)之促效劑的組合療法
|
|
CA3094235A1
(en)
|
2018-04-13 |
2019-10-17 |
F. Hoffmann-La Roche Ag |
Her2-targeting antigen binding molecules comprising 4-1bbl
|
|
US20200223925A1
(en)
|
2018-12-21 |
2020-07-16 |
Hoffmann-La Roche Inc. |
Tumor-targeted superagonistic cd28 antigen binding molecules
|
|
MX2021007320A
(es)
|
2018-12-21 |
2021-07-07 |
Hoffmann La Roche |
Moleculas agonistas de union al antigeno cd28 que actuan sobre el tumor.
|
|
WO2020208049A1
(en)
|
2019-04-12 |
2020-10-15 |
F. Hoffmann-La Roche Ag |
Bispecific antigen binding molecules comprising lipocalin muteins
|
|
CA3141378A1
(en)
|
2019-06-26 |
2020-12-30 |
F. Hoffmann-La Roche Ag |
Fusion of an antibody binding cea and 4-1bbl
|
|
EP3990492A1
(en)
|
2019-06-27 |
2022-05-04 |
F. Hoffmann-La Roche AG |
Novel icos antibodies and tumor-targeted antigen binding molecules comprising them
|
|
TW202115115A
(zh)
|
2019-07-02 |
2021-04-16 |
瑞士商赫孚孟拉羅股份公司 |
免疫結合物
|
|
JP2022543551A
(ja)
|
2019-07-31 |
2022-10-13 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｇｐｒｃ５ｄに結合する抗体
|
|
CN119192386A
(zh)
|
2019-07-31 |
2024-12-27 |
豪夫迈·罗氏有限公司 |
与gprc5d结合的抗体
|
|
CN114929734A
(zh)
|
2020-01-09 |
2022-08-19 |
豪夫迈·罗氏有限公司 |
新型含有4-1bbl三聚体的抗原结合分子
|
|
MX2022012541A
(es)
|
2020-04-15 |
2022-11-07 |
Hoffmann La Roche |
Inmunoconjugados.
|
|
MX2022015203A
(es)
|
2020-06-19 |
2023-01-05 |
Hoffmann La Roche |
Moleculas de union al dominio fc de activacion inmunitaria.
|
|
CA3177239A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Protease-activated t cell bispecific antibodies
|
|
MX2022015795A
(es)
|
2020-06-23 |
2023-01-24 |
Hoffmann La Roche |
Moleculas agonistas de union al antigeno cd28 que se dirigen a her2.
|
|
EP4172203A1
(en)
|
2020-06-25 |
2023-05-03 |
F. Hoffmann-La Roche AG |
Anti-cd3/anti-cd28 bispecific antigen binding molecules
|
|
AU2021393752A1
(en)
|
2020-12-04 |
2023-05-18 |
F. Hoffmann-La Roche Ag |
Ph-dependent mutant interleukin-2 polypeptides
|
|
WO2022148853A1
(en)
|
2021-01-11 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
|
EP4304724A1
(en)
|
2021-03-09 |
2024-01-17 |
F. Hoffmann-La Roche AG |
Combination therapy of pd-1-targeted il-2 variant immunoconjugate and anti-tyrp1/anti-cd3 bispecific antibodies
|
|
EP4304723A1
(en)
|
2021-03-09 |
2024-01-17 |
F. Hoffmann-La Roche AG |
Combination therapy of pd-1-targeted il-2 variant immunoconjugates and fap/4-1bb binding molecules
|
|
EP4314032A1
(en)
|
2021-03-30 |
2024-02-07 |
F. Hoffmann-La Roche AG |
Protease-activated polypeptides
|
|
AR126009A1
(es)
|
2021-06-02 |
2023-08-30 |
Hoffmann La Roche |
Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
|
|
CN118139648A
(zh)
|
2021-10-14 |
2024-06-04 |
豪夫迈·罗氏有限公司 |
用于治疗癌症的替代的PD1-IL7v免疫缀合物
|
|
AU2022362681A1
(en)
|
2021-10-14 |
2024-04-04 |
F. Hoffmann-La Roche Ag |
New interleukin-7 immunoconjugates
|
|
JP2024543257A
(ja)
|
2021-11-26 |
2024-11-20 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗ｔｙｒｐ１／抗ｃｄ３二重特異性抗体およびｔｙｒｐ１特異性抗体の併用療法
|
|
AR128876A1
(es)
|
2022-03-28 |
2024-06-19 |
Hoffmann La Roche |
Anticuerpos biespecíficos de linfocitos t activables con proteasa folr1 mejorados
|
|
WO2024068572A1
(en)
|
2022-09-28 |
2024-04-04 |
F. Hoffmann-La Roche Ag |
Improved protease-activatable t cell bispecific antibodies
|
|
CN119948048A
(zh)
|
2022-09-29 |
2025-05-06 |
豪夫迈·罗氏有限公司 |
蛋白酶活化的多肽
|
|
WO2024100170A1
(en)
|
2022-11-11 |
2024-05-16 |
F. Hoffmann-La Roche Ag |
Antibodies binding to hla-a*02/foxp3
|
|
EP4651886A1
(en)
|
2023-01-20 |
2025-11-26 |
F. Hoffmann-La Roche AG |
Immunoconjugates
|
|
WO2024246083A1
(en)
|
2023-06-01 |
2024-12-05 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies targeting bcma and cd28
|
|
WO2024246086A1
(en)
|
2023-06-01 |
2024-12-05 |
F. Hoffmann-La Roche Ag |
Immunostimulatory antigen binding molecules that specifically bind to bcma
|
|
WO2025202147A1
(en)
|
2024-03-27 |
2025-10-02 |
F. Hoffmann-La Roche Ag |
Interleukin-7 immunoconjugates
|
|
WO2025233304A1
(en)
|
2024-05-08 |
2025-11-13 |
F. Hoffmann-La Roche Ag |
Recombinant fc domain – il7 variant polypeptides and combination therapy with membrane-anchored antigen binding polypeptides
|